2/2
09:46 am
rapp
Rating for RAPP
Low
Report
Rating for RAPP
2/2
09:46 am
rapp
Rating for RAPP
Low
Report
Rating for RAPP
2/2
07:00 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $43.00 price target on the stock.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $43.00 price target on the stock.
2/2
05:58 am
rapp
Rapport Therapeutics initiated with an Overweight at Wells Fargo
Medium
Report
Rapport Therapeutics initiated with an Overweight at Wells Fargo
2/2
05:58 am
rapp
Rapport Therapeutics initiated with an Overweight at Wells Fargo
Medium
Report
Rapport Therapeutics initiated with an Overweight at Wells Fargo
1/8
07:17 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/9
07:21 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
08:07 am
rapp
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.
Low
Report
Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.
12/8
05:45 am
rapp
Rating for RAPP
Low
Report
Rating for RAPP